

Contents

<i>Preface</i>	(vii)
<i>Acknowledgements</i>	(ix)
<i>Abbreviations</i>	(xxi)

PART I GENERAL PRINCIPLES

Chapter - 1

Branches and Divisions of Pharmacology

Introduction.....	3
Drug	3
Drug Sources	4
Drug Nomenclature.....	4
The Nature of Drugs.....	4
Branches of Pharmacology	5
Hypersensitivity	9
Type I Hypersensitivity	9
Type II Hypersensitivity	10
Type III Hypersensitivity.....	10
Type IV Hypersensitivity.....	11
Drug Response and Factors affecting Drug Response.....	12
Important Factors Modifying Drug Action.....	12

Chapter - 2

Pharmacokinetics of Drugs

Bitransport of Drug	22
Composition and Structure of Membranes	22
Lipids.....	22
Proteins.....	23
Transfer through the Lipid Bilayer.....	23
Transfer through Membrane Protein Structures	25

Transport by Exocytosis and Endocytosis	26
Drug Absorption.....	27
Distribution of Drugs	30
Drug Distribution from Blood	31
Binding to Proteins.....	31
Tissue Distribution of Drugs	32
Excretion of Drugs	34
Different Routes of Drug Excretion	35
Other Routes of Excretion.....	38
Milk Excretion.....	38
Sweat Excretion	38
Mammary Excretion	38
Excretion by various Secretions.....	38
Artificial Methods of Excretion	39
Digestive Excretion	39
Accelerated Renal Excretion	39
Artificial Excretion	39
Theoretical Pharmacokinetics	39
References	41

Chapter - 3

Drug Receptors and Pharmacodynamics

Introduction.....	42
Drug-Receptor Complex Nomenclature.....	42
Some Characteristics of Receptors	43
Drug Receptor Interactions	55
Receptor Site Theories	56
Pharmacodynamics	57
References	59

Chapter - 4

Drug Biotransformation

Introduction.....	60
Sites of Drug Metabolism	60
Drug Metabolizing Enzymes	61
Phase I Reactions	62
Oxidative Reactions	64
Reductive Reactions	68
Hydrolytic Reactions.....	68
Phase II Reactions	70
Factors Affecting Biotransformation of Drug	77
Enzyme Inhibition	78
Presystemic Metabolism/First Pass Effect/Route of Administration.....	79
Genetic Variations.....	79
Species Differences	79
Exposure to Pollutants from Environment or Industry	79
Age.....	79
Sex.....	80
Drug-Drug Interaction	80
Nutrition	80
Pathological Conditions.....	80
Circadian Rhythm.....	80
References.....	80

Chapter - 5

Drug Discovery and Development

Introduction.....	81
The Discovery Process	81
Pre Discovery	81
Target Identification.....	81
Target Prioritization/Validation	81
Lead Identification	82
Lead Optimization	82
Early Safety Tests.....	82
Lead Optimization.....	82
Preclinical Testing.....	83
The Development Process	83
Clinical Trial Design.....	83
Phase 1 Clinical Trial.....	84
Phase 2 Clinical Trial.....	84
Phase 3 Clinical Trial.....	84

New Drug Application (NDA) and Approval.....	84
Submit Application for Approval to FDA.....	84
Benefit Vs. Risk	85
Manufacturing	85
Ongoing Studies and Phase 4 Trials	85
Conclusion.....	88
References	88

Chapter - 6

Pharmacovigilance

Definition	89
Vigilance.....	89
History.....	89
Current Scenario	89
Major Aims	90
Common ADRs	90
Why Pharmacovigilance?	90
Risk	90
Limitations of Phase 1-3 Clinical Trials.....	91
Withdrawn Drugs.....	91
(in the US, Since 2000)	91
Definitions.....	91
Adverse drug reaction (Table 7.1)	91
Adverse event.....	92
Side effect	92
Outcome of PVG	92
Drug Outcomes	92
WHO Programme for International Drug Monitoring	92
WHO Collaborating Centre (Uppsala Monitoring Centre).....	92
Subsequently Aims to.....	92
National Pharmacovigilance Policy	93
Milestones	93
Expected and Unexpected Events	93
Key Facts	93
Karch and Lasagna	94
The literature (9 points of consideration - Morges, Switzerland, 1981).....	94
Methods used in Pharmacovigilance	95
Who Should Report Safety Data	97
What to Report - WHO Recommendations	97
Where to Report	97

Role of NPV Centre	100
Limitations.....	100
Future Strategies and Proposals	100
So...What is Our Role?	100
References.....	100

Chapter - 7

Essential Drugs

Definition.....	102
The Concept of Essential Medicines	102
Definition.....	102
History of the WHO Model List of Essential Drugs	102
Purpose	102
Implementation	103
Choice of Essential Drug	103
Seven Steps to Get a New Medicine on.....	103
Systematic and Transparent Process.....	103
Steps in Review of Applications to the Model List.....	103
Role of Treatment Cost and Global Cost-effectiveness Analyses	104
Presentation of Recommendations, Report Presentation of Recommendations	104
Report, web site, translations.....	104
Pharmaceutical Dosage Forms – Guidelines for in the List of Essential Drugs	105
1998-10 th List Model List of.....	105
Essential Drugs Salient Features	105
Conclusion.....	106

Chapter – 8

Abnormal Actions of Drugs

Adverse Drug Event	107
The Risk to Benefit Ratio	107
Classification	108
Predictable Reactions (Type A).....	108
Seriousness and Severity	108
Unpredictable Reactions (Type B).....	108
Overall Drug Risk.....	109
Location	109
Mechanisms	109
Abnormal Pharmacokinetics.....	109

Detecting Adverse Effects.....	111
Prevention of Adverse Drug Reactions	111
Hypersensitivity.....	111
Drug Habitation	115
Drug Allergy.....	115
References	118

Chapter – 9

Drug Interactions

Definition	119
Prevalence	119
Factors Contributing to Drug Interactions.....	119
Mechanisms of Drug Interaction.....	120
Drug Distribution Interactions	122
Protein-binding Interactions.....	122
Drug Excretion Interactions.....	124
Drug food Interactions	134
Reducing the Risk of Drug Interactions – Principles of Drug Interactions Management	139
References	140

PART - II

DRUGS AFFECTING AUTONOMIC NERVOUS SYSTEM

Chapter - 10

General Considerations of Autonomic Nervous System

Anatomy.....	143
Sympathetic Division	143
Parasympathetic Division.....	144
Sensory Neurons.....	145
Motor Neurons.....	145
Function.....	146
Sympathetic Nervous System.....	146
Parasympathetic Nervous System	146
Neurotransmitters and Pharmacology	146
References	149

Chapter - 11

Cholinergic Drugs

The Cholinergic Neuron.....	150
Neurotransmission at Cholinergic Neurons	150
Cholinergic Receptors (Cholinoceptors)	152
Muscarinic Receptors (M).....	152
Molecular Mechanism at Muscarinic Receptors	152
Nicotinic Receptors.....	153
Molecular Mechanisms/Signal Transduction at Nicotinic Receptors.....	153
Parasympathomimetic Drugs or Cholinergic Drugs or Cholinomimetic Drugs.....	153
Acetylcholine Effects	155
Muscarinic Effects.....	155
Cardiac Effects.....	155
Vascular Effects	155
Effects on Smooth Muscles (Except Vascular)	155
Effects on Secretions (Receptors M ₃)	156
Effects on the Eye (Receptors M ₃)	156
Central Effects	156
Nicotinic Effects	156
Autonomic Ganglia Effects.....	156
Neuromuscular Junction Effects.....	156
Central Nervous System Effects	158
Parasympathomimetic Drugs.....	158
Directly acting Cholinergic Drugs.....	158
Cholinomimetic Alkaloids.....	159
Acetylcholinesterase	162
Reversible Inhibitors	162
Mechanisms of Action of Indirect (Reversible) Cholinergic Agonists.....	164
Irreversible Inhibitors.....	164
Anticholinesterase/Organophosphorus Poisoning and Treatment.....	165
References.....	166

Chapter - 12

Muscarinic Receptor Blocking Drugs

Classification	167
----------------------	-----

Basic Pharmacology of Muscarinic

Receptor Blocking Drugs	168
Pharmacokinetics	168
Mechanism of Action.....	168
Effects	168
Toxicity of Antimuscarinic Drugs	172
Predictable Toxicities	172
Unpredictable Toxicities.....	172
Clinical Uses	172
Mydriatic Agents.....	172
Gastric Acid Secretion Inhibitors	172
Bronchodilators	173
With Vesical Indications.....	173
Used as Antispasmodics.....	173
Used as Antiparkinsonians	173
Uses in Urology	173
Uses in Anaesthesiology.....	173
Other Drugs	176
Contraindications and Cautions	176
References	176

Chapter - 13

Adrenergic Drugs

The Adrenergic Neuron.....	177
Neurotransmission at Adrenergic Neurons	177
Synthesis, Storage and Release of Catecholamines.....	178
Metabolism and Distribution of Catecholamines	179
Adrenergic Receptors.....	179
α Receptors	181
β Receptors.....	181
Classification of Adrenergic Agonists.....	182
Structure Activity Relationship of Adrenergic Drugs	183
Direct-Acting Agonists.....	184
Epinephrine (EP)	184
Norepinephrine (NE).....	186
Dopamine	187
Amphetamine	188
Ephedrine	188
Isoproterenol.....	189

Selective Adrenergic Agonists.....	189
Phenylephrine, Metaraminol, and Methoxamine	189
Dobutamine	189
Terbutaline and Albuterol	189
References	190

Chapter -14

Adrenergic Blocking Drugs

Classification of Sympatholytic Drugs	191
Alpha-Adrenergic Antagonists (Blockers)	191
Classification of α Antagonist	191
Quinazoline Derivatives	191
Imidazoline Derivative	193
Haloalkylamines	193
Clinical Pharmacology of α -receptor Blocking Drugs.....	194
β -Adrenergic Antagonists.....	195
Nonselective- β Adrenergic Receptor Antagonists	199
Selective- β_1 Adrenergic Receptor Antagonists.....	199
Therapeutic uses for Beta Adrenergic Receptor Antagonists (Blockers).....	200
Hyperthyroidism	200
Glaucoma	200
Anxiety States.....	201
Migraine.....	201
Angina Pectoris	201
Acute Myocardial Infarction	201
Supraventricular Tachycardias and Ventricular Dysrhythmias	201
Hypertension.....	201
Adverse Effects of β Adrenergic Receptor Antagonists	202
Drugs with Combined α -and β -Blocking Activity	202
Labetalol.....	202
Other Compounds	204
References.....	204

Chapter - 15

Ganglionic Stimulating and Blocking Agents

Introduction.....	205
Mechanism of Action.....	205
Pharmacological Actions	206
Peripheral Nervous System	206
Central Nervous System.....	206
Cardiovascular System.....	207
Gastrointestinal Tract.....	207
Exocrine Glands.....	207
Pharmacokinetics	207
Acute Nicotine Poisoning.....	207
Therapy	208
Lobeline	208
Other Ganglionic Stimulants	208
Ganglion-Blocking Drugs	209
Classification.....	209
Chemistry and Pharmacokinetics	209
Pharmacodynamics.....	210
Organ System Effects.....	210
Clinical Applications and Toxicity.....	210
References	212

Chapter - 16

Skeletal Muscle Relaxants

Introduction.....	213
Neuromuscular Physiology.....	213
Classification	214
Mechanism of Skeletal Muscle Contraction.....	214
Nondepolarizing Agents	215
Mechanism of Action.....	215
Pharmacological Actions.....	215
Clinical Uses.....	215
Adverse Effects and Precautions.....	215
Other Nondepolarizing Blockers of Importance	216
Classification According to Duration of Action	216
Depolarizing Agents.....	218
Drugs: Suxamethonium (succinylcholine) Decamethonium	218
Succinylcholine.....	218
Uses of Neuromuscular Blocking Drugs..	220

Central Acting Skeletal Muscle Relaxants (Spasmolytic Drugs).....	221
Methocarbamol.....	222
Baclofen.....	222
Dantrolene.....	222
Botulinum Toxin Type A,B.....	222
Benzodiazepines (diazepam, lorazepam, clonazepam, etc.).....	223
Tizanidine.....	223
Drugs Used to Treat Acute Local Muscle Spasm.....	223
Cyclobenzaprine.....	224
Orphenadrine.....	225
Metaxalone.....	225
Carisoprodol.....	225
Other Centrally Acting Spasmolytic Drugs.....	225
References.....	225

PART - III
DRUGS AFFECTING
CENTRAL NERVOUS SYSTEM

Chapter - 17

General Considerations of Central Nervous System

Macroanatomy.....	229
Microanatomy of the Brain.....	230
Central Neurotransmitters.....	231
Biogenic Amines.....	231
Acetylcholine.....	238
GABA and Glycine.....	238
Amino Acids.....	245
Neuropeptides (polypeptides).....	247
Purine Nucleotides.....	247
P ₂ Receptors and Actions.....	249
Peptides.....	250
References.....	251

Chapter - 18

Neurodegenerative Diseases

Introduction.....	252
Alzheimer's Disease.....	252
Pathophysiology.....	252

Symptoms.....	253
Treatment.....	253
Parkinson's Disease.....	255
Pathophysiology.....	255
Symptoms.....	255
Treatment.....	256
Huntington Disease.....	265
Symptoms and Stages of HD.....	265
The Stages of HD.....	266
Diagnosis.....	267
Juvenile Huntington's Disease.....	267
Symptomatic Treatment and Management.....	267
References.....	270

Chapter - 19

General Anaesthetics

Principle of General Anaesthesia.....	272
Stages of Anesthesia.....	272
Theory of General Anaesthetics.....	274
Lipid Theory.....	274
Classification.....	275
Intravenous Anaesthetics or Induction Agents.....	275
Inhaled Anaesthetics.....	280
Preanaesthetic Medication.....	286
Objectives of Preanaesthetic Medication.....	286
Sedatives/ Anxiolytics.....	286
Opioid Analgesics.....	287
Anticholinergic Drugs.....	287
Antiemetics-Antiemetic Effect.....	287
References.....	288

Chapter - 20

Sedative Hypnotics and Anxiolytic Drugs

Sleep.....	289
Genesis of Sleep.....	289
Classification.....	290
Azapirones.....	290
Benzodiazepines.....	291
Barbiturates.....	296
Other Benzodiazepine Receptor Agonists.....	298

Sedatives and Anxiolytics with other Major Uses.....	298	Causes for Depression.....	314
Antihistamines	298	The Monoamine Theory.....	314
β - Adrenoceptor Blocking Agents	299	Symptoms	314
Antidepressants	299	Treatment	315
Older Sedative-Hypnotics and Anxiolytic Agents.....	299	Classification.....	315
Non-prescription Drugs	299	Antidepressants.....	315
References.....	300	Selective Serotonin Reuptake Inhibitors	315
Chapter - 21		Mechanism of Action.....	315
Neuroleptics		Pharmacokinetics	316
Introduction.....	301	Therapeutic Uses	316
Schizophrenia	301	Adverse Effects	316
Symptoms	301	Drug Interactions.....	317
Types	302	Serotonin-Norepinephrine Reuptake Inhibitors	317
Theories of Schizophrenia	302	Types of SNRIs	317
Dopamine Hypothesis.....	302	Mechanism of Action.....	317
Serotonin Hypothesis.....	302	Adverse Effects	317
Glutamate Hypothesis	303	Atypical Antidepressants	317
Definitions	303	Mechanism of Action.....	317
Ideal Antipsychotic.....	303	Atypical Antidepressants Approved to Treat Depression	318
Classification of		Adverse Effects of Atypical Antidepressants.....	318
Antipsychotic Drugs	303	Tricyclic and Tetracyclic Antidepressants.....	318
Distinction between ‘typical’ and ‘atypical’ groups is not clearly defined, but rests on:.....	303	Mechanism of Action.....	318
Mechanism of Action	304	Cyclic Antidepressants Approved to Treat Depression.....	318
Phenothiazines	305	Adverse Effects of Tricyclic Antidepressants.....	319
Chlorpromazine	305	MAO Inhibitors	319
Pharmacological Effects and Mechanism	306	Mechanism of Action.....	319
Pharmacokinetics.....	306	Risks are Associated with MAO Inhibitors	319
Adverse Effects.....	306	Medications to Avoid	319
Therapeutic Uses.....	307	Foods to Avoid	320
Phenothiazines - Drug Interactions.....	309	Adverse Effects	320
Nonphenothiazines	309	References	320
First-Generation “Typical” Antipsychotics.....	309	Chapter - 23	
Second-Generation “Atypical” Antipsychotics.....	309	Antiepileptic Drugs	
References.....	313	Introduction.....	321
Chapter - 22		Pathophysiology	321
Antidepressants		Types of Seizures	321
Introduction.....	314	Partial Seizures	321

Generalised Seizures	322
Causes for Acute Seizures	323
Treatment	324
Strategies.....	324
Classification of Antiepileptics	325
Sodium Channel Blocking Agents	327
Phenytoin.....	327
Carbamazepine	328
Oxcarbazepine.....	329
Lamotrigine	329
Zonisamide	329
Topiramate.....	330
Sodium Valproate or Valproic Acid	330
Drugs that Primarily Enhance the Action of GABA	331
Benzodiazepines	331
Vigabatrin	332
Tiagabine.....	332
Phenobarbital and Primidone (Mysoline)	332
Agents that Block T-Calcium Channels.....	333
Ethosuximide.....	333
Agents whose Mechanism of Action is not Known	333
Felbamate.....	333
Gabapentin.....	333
Levetiracetam	334
Anticonvulsant Drugs and Pregnancy	334
Treatment of Febrile Seizures	335
Treatment of Status Epilepticus.....	335
References.....	335

Chapter - 24

Opioid Analgesics

Introduction.....	336
Endogenous Opioids.....	337
Enkephalins, Endorphins, Dynorphins, Endomorphins.....	338
Opioid Receptors.....	338
Mechanism of Opioid Receptor Function.....	339
Classification of Opioid Analgesic Drugs.....	339
Pharmacokinetics	339
Cellular Mechanisms of Action.....	340

Pharmacological Effects.....	340
Tolerance and Physical Dependence	341
Morphine	342
Other Opioids.....	343
Meperidine or Pethidine.....	343
Methadone	344
Fentanyl	344
Heroin	344
Codeine	344
Oxycodone	344
Propoxyphene.....	345
Mixed Agonist-Antagonist and Partial Agonists	345
Buprenorphine	345
Pharmacokinetics	345
Antagonists	346
References	347

Chapter - 25

CNS Stimulants

Introduction.....	348
Classification.....	348
Analeptic Stimulants.....	349
Mechanism of Action.....	349
Pharmacokinetics	350
Clinical Uses.....	350
Psychomotor Stimulants	350
Pharmacokinetics	351
Clinical Uses.....	351
Adverse Effects	351
Xanthines	351
Pharmacokinetics	352
Mechanism of Action.....	352
Clinical Uses.....	353
Adverse Effects	353
Abuse of Xanthines	353
Drug Interactions.....	353
References	353

Chapter - 26

Drug Dependence and Drug Abuse

Opioids	355
Extent and Pattern of Abuse	355
Pharmacological Aspects	356
Tolerance and Dependence.....	356
Treatment of Opioid Dependence.....	356

Stimulants.....	357	Combinations	369
Extent and Pattern of Abuse.....	357	Mechanism of Action.....	369
Pharmacological Aspects.....	357	Various Techniques of	
Mechanism of Action	357	Local Anesthesia	371
Tolerance and Dependence	358	Clinical Techniques Include.....	371
Other Adverse Effects of		Pharmacokinetics	372
Chronic Abuse.....	358	Adverse Effects.....	373
Nicotine	358	Localized Adverse Effects	373
Sedative-Hypnotics	358	General Adverse Effects	373
Pharmacological Aspects.....	358	Central Nervous System.....	373
Tolerance and Dependence	359	Cardiovascular System.....	374
Ethanol.....	359	Hypersensitivity/Allergy	374
Chemistry.....	359	Methemoglobinemia	374
Absorption, Distribution, Metabolism		Specific Uses	374
and Excretion.....	360	Acute Pain	374
Mechanism of Action	360	Chronic Pain.....	374
Pharmacological Actions on		Surgery and Dentistry	374
Central Nervous System	361	Other Uses	375
Other Body Systems	361	Factors Affecting Local	
Adverse Effects.....	361	Anaesthetic Activity Clinically	375
Treatment for Acute Intoxication	362	Dose.....	375
Alcoholism.....	362	Addition of Vasoconstrictors.....	375
Marijuana.....	363	Site of Injection	376
Chemistry.....	363	Carbonation and pH Adjustment	376
Pharmacokinetic Aspects.....	363	Mixtures of Local Anesthetics	376
Mechanism of Action	363	Pregnancy	376
Pharmacological Actions on		Medication Interactions with	
Central Nervous System	363	Local Anesthetics	377
Other Organ Systems	364	References	377
Adverse Effects.....	364	Chapter - 28	
Hallucinogens	364	Drugs used in Myasthenia Gravis	
Extent and Pattern of Abuse.....	365	Medications.....	378
Pharmacological Aspects.....	365	Anticholinesterase Medication.....	378
Tolerance and Dependence	366	Immunosuppressant Medications	378
Treatment Strategies.....	366	Prednisone	379
Mechanism of Action	366	Thymectomy.....	379
Inhalants	366	Intravenous Immune Globulin (IVIg).....	379
Designer Drugs.....	367	Plasmapheresis.....	380
Anabolic Steroids.....	367	Chapter - 29	
References.....	367	Nootropics	
Chapter - 27		Mechanisms of Action	381
Local Anaesthetics		Indications.....	381
Introduction.....	368	Side Effects	381
Chemistry.....	368	References	384
Classification	368	Index.....	385